Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 63

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 63
---
 by the Shareholders is expected to be approximately equal to the cash value per Common Share that will remain in the Company, after deducting certain 
 transaction costs, the aggregate amount of outstanding liabilities, and a transaction fee to the Purchaser.                                                                                                                                            |

| • |     | Results of a Strategic Review Process — The Arrangement is the result of a reasoned,                                                                                                                                                                      
 fully informed process. The Company conducted a fulsome strategic process, with the assistance of its outside legal counsels and the Company’s financial advisor, to explore potential strategic alternatives to maximize shareholder value. The          
 Company conducted a tailored market search, ultimately focusing on potential financial buyers, because the Company believes that cash acquisition transaction proposals offered certainty of closing and value to the Shareholders. There were no         
 alternative transactions that the Company considered more advantageous to the Shareholders than the Arrangement. The Company also considered alternatives to a strategic process, including a liquidation of the Company to distribute any available cash 
 to Shareholders.                                                                                                                                                                                                                                          |

| • |     | No Financing Condition — The Arrangement is not subject to a financing condition and XRC                                                        
 has unconditionally and irrevocably guaranteed the full and timely performance and satisfaction of Purchaser’s obligations under the Agreement. |

| • |     | Potential Additional Consideration —  The CVR Consideration provides Shareholders with                                                                                              
 an opportunity to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement. See “The CVR Agreement.” |

35

| • |     | Reasonable Holdback and Purchaser Fee — The amount of cash held back at closing,                                                                                                                                                                       
 including a transaction fee of US$4,000,000 to be retained by the Purchaser and deductions for other customary fees, expenses and liabilities, are reasonable and maximize the amount of cash to be distributed to Shareholders in connection with the 
 Arrangement.                                                                                                                                                                                                                                           |

| • |     | Prospects of the Company on a Standalone Basis — The Transaction Committee reviewed and                                                                                                                                                           
 assessed the assets, liabilities and financial condition of the Company if it pursued another business on a standalone basis, which belief was based on and informed by consideration of a number of factors, risks and uncertainties, including: |

| • |     | the Company’s historical results of operations, including the Company’s strategic reprioritization; |

| • |